The rise of GLP-1 agonists, a class of medications used in the treatment of diabetes and obesity, has been a hotly debated topic amongst the medical and investment fraternities. In this episode, Andrew Dale discusses the potential risks and opportunities these medications pose to the health care sector and shares his thoughts on the implications for one high quality Australian company.

Learn more at ecpam.com

Follow us on LinkedIn

Subscribe for more insights

This publication is intended for professional, wholesale investors and is not suitable for retail clients. ECP Asset Management Pty Ltd (ECP), ACN 158 827 582 (Corporate Authorised Representative 441986 of AFSL 421704), believe the information contained in this communication is reliable, however, its accuracy, reliability or completeness is not guaranteed. To the extent permitted by law, ECP denies all liability to any person relying on the information in respect of any loss or damage (including consequential loss or damage) however caused, which may be suffered or arising directly or indirectly in respect of such information contained in this communication. Any opinions or forecasts reflect the judgment and assumptions of ECP on the basis of information at the date of publication and may later change without notice. The information is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making an investment decision. Past performance is not a reliable indicator of future performance. This publication is prepared without taking account of any person’s objectives, financial situation or needs and is intended for general information only.